| Variables | Early abciximab | Late abciximab | Early tirofiban | Late tirofiban | Early eptifibatide | Late eptifibatide |
| (n = 302) | (n = 310) | (n = 311) | (n = 321) | (n = 227) | (n = 191) | |
| Age, years | ||||||
| Median | 61 | 62 | 62 | 62 | 58 | 59 |
| 25–75th percentiles | 52–69 | 52–72 | 54–70 | 52–70 | 50–70 | 51–68 |
| Sex, n (%) | 228/302 (75.5%) | 239/310 (77.1%) | 249/311 (80.1%) | 259/321 (80.7%) | 165/227 (72.7%) | 143/191 (74.9%) |
| Hypertension, n (%) | 143/301 (47.5%) | 143/310 (46.1%) | 97/311 (31.2%) | 110/321 (34.3%) | 113/226 (50.0%) | 94/191 (49.2%) |
| Diabetes, n (%) | 61/302 (20.2%) | 69/310 (22.3%) | 37/311 (11.9%) | 42/321 (13.1%) | 35/227 (15.4%) | 37/191 (19.4%) |
| Previous MI, n (%) | 14/301 (4.7%) | 26/310 (8.4%) | 21/310 (6.8%) | 31/321 (9.7%) | 32/227 (14.1%) | 23/191 (12.0%) |
| Previous revascularisation, n (%) | 9/254 (3.5%) | 13/258 (5.0%) | 22/311 (7.1%) | 22/321 (6.9%) | 30/227 (13.2%) | 24/191 (12.6%) |
| Smoking, n (%) | 151/302 (50.0%) | 146/310 (47.1%) | 176/311 (56.6%) | 196/321 (61.1%) | 113/227 (49.8%) | 77/191 (40.3%) |
| Hypercholesterolemia, n (%) | 135/302 (44.7%) | 142/309 (46.0%) | 78/311 (25.1%) | 90/321 (28.0%) | 85/227 (37.4%) | 77/190 (40.5%) |
| Killip class III/IV, n (%) | 15/302 (4.9%) | 14/310 (4.4%) | 3/251 (1.2%) | 4/256 (1.6%) | 15/169 (9.2%) | 15/139 (10.8%) |
| Anterior MI, n (%) | 153/302 (50.7%) | 157/310 (50.6%) | 127/311 (40.8%) | 138/321 (43.0%) | 81/218 (37.2%) | 74/188 (39.4%) |
| Symptom onset to Gp IIb–IIIa inhibitor time, minutes* | ||||||
| Median | 130 | 203 | 64 | 191 | 150 | 199 |
| 25–75th percentiles | 800–203 | 145–300 | 50–85 | 145–264 | 95–257 | 138–267 |
| Ischaemia time, minutes | ||||||
| Median | 194 | 208 | 193 | 198 | 191 | 210 |
| 25–75th percentiles | 145–271 | 150–300 | 150–249 | 150–270 | 138–295 | 147–303 |
| Infarct-related artery | ||||||
| LAD, n (%) | 151 (50%) | 153 (49.4%) | 123 (39.5%) | 134 (41.7%) | 77 (33.9%) | 74 (38.7%) |
| CX, n (%) | 34 (11.3%) | 30(9.7%) | 51 (16.4%) | 41 (12.8%) | 39 (17.2%) | 29 (15.2%) |
| RCA, n (%) | 113 (37.4%) | 122 (39.4%) | 123 (39.5%) | 131 (40.8%) | 103 (45.3%) | 83 (43.5%) |
| GRAFT, n (%) | 0 | 6 (0.7%) | 2 (0.6%) | 4 (1.2%) | 4 (1.8%) | 2 (1.0%) |
| LM, n (%) | 0 | 3 (1.0%) | 4 (1.3%) | 1 (0.3%) | 0 | 1 (0.5%) |
| Multivessel disease, n (%) | 120/254 (47.2%) | 142/258 (55.0%) | 150/282 (53.2%) | 147/289 (50.9%) | 167/221 (75.6%) | 144/190 (75.8%) |
| Follow-up | ||||||
| Median | 180 | 180 | 357 | 356 | 30 | 30 |
| 25–75th percentiles | 30–360 | 30–360 | 346–360 | 342–360 | 30–30 | 30–30 |
All p values are not significant except for the time from symptom onset to administration of Gp IIb–IIIa inhibitors* (p<0.001).
CX, circumflex artery; Gp, glycoprotein; LAD, left descending coronary artery; LM, left main artery; MI, myocardial infarction; RCA, right coronary artery.